返回
HBM Holdings Limited（2142.HK）價格
2142.HK 股價走勢圖
HBM HOLDINGS-B (2142.HK)
HBM Holdings Limited
HK$14.38
-1.03%
$-0.14
休市： Jan 16, 16:00:00 HKT
關鍵數據
前收市價
$14.53
開盤價
$14.53
當日範圍
$14.08 - $14.68
52週區間
$2.9 - $17.98
交易量
2.8M
平均成交量
4.4M
每股盈餘 (TTM)
0.73
股息收益率
--
市值
$12.0B
什麼是 HBM HOLDINGS-B？
HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. The company is headquartered in Suzhou, Jiangsu and currently employs 210 full-time employees. The company went IPO on 2020-12-10. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The firm provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
